Skyhawk Therapeutics nabs Peloton exec and cancer R&D veteran as VP of oncology biology

Two months after Merck announced a billion-dollar-plus deal to buy out late-stage cancer biotech Peloton, some of its staffers are finding new homes.

This is good news for RNA startup Skyhawk Therapeutics, which has nabbed Peloton’s former VP of biology, Dr. Tai Wong, as its own VP of oncology biology.

Continue reading on FierceBiotech

By MIT Sloan CDO